Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development

Ann Oncol. 2016 Jun;27(6):1165-1170. doi: 10.1093/annonc/mdw129. Epub 2016 Mar 8.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Cooperative Behavior*
  • Drug Approval / methods
  • Drug Design*
  • Drug Discovery / methods*
  • Drug Discovery / trends
  • Humans
  • Lung Neoplasms / drug therapy
  • Piperazines / chemistry
  • Piperazines / therapeutic use*
  • Time Factors

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • Piperazines
  • osimertinib